Abiomed says AHA analysis of Impella 'flawed'
The Abiomed medical office is issuing a publication review of the observational analysis of Impella that was presented by Amin et al. at the American Heart Association Conference on November 17, stating in a related press release that "the AHA analysis is flawed because: The data source has significant limitations, containing just a fraction of Impella patients and unable to delineate between common adverse events; The Impella patients were much sicker and had greater baseline and procedural risks; The analysis excluded the costliest IABP patients who were escalated to other therapies Additionally, the conclusion is aggressive because administrative coding data cannot delineate between adverse events common to high-risk patients and device related events. A video summarizing the review's findings was also posted by the company on the site ProtectedPCI.com. Reference Link